- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT07306832
Een onderzoek om bijwerkingen te beoordelen en te bestuderen hoe intraveneus (IV) pivekimab sunirine zich door het lichaam verplaatst bij pediatrische deelnemers met recidiverende of refractaire acute myeloïde leukemie (AML)
Een Fase 1b-studie naar de veiligheid en farmacokinetiek van Pivekimab Sunirine bij pediatrische patiënten met recidiverend of refractair acuut myeloïde leukemie (AML)
Acute myeloid leukemia (AML) is an aggressive blood cancer, withwith few options for participants who relapse after treatment or who don't respond to treatment. This study will assess the adverse events and how pivekimab sunirine moves through the body in pediatric participants with relapsed or refractory (R/R) AML.
Pivekimab sunirine is a drug being evaluated in the treatment of AML. This is an open label, single arm study, participants will be enrolled in 1 of the 3 cohorts based on their age and will receive pivekimab sunirine at a dose based on their weight. Around 18 pediatric participants with a diagnosis of AML will be enrolled in the study at approximately 30 sites around the world.
Participants will receive intravenous (IV) pivekimab sunirine alone. The total study duration is approximately 28 months.
There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, and checking for side effects.
Studie Overzicht
Toestand
Conditie
Interventie / Behandeling
Studietype
Inschrijving (Geschat)
Fase
- Fase 1
Contacten en locaties
Studiecontact
- Naam: ABBVIE CALL CENTER
- Telefoonnummer: 844-663-3742
- E-mail: abbvieclinicaltrials@abbvie.com
Studie Locaties
-
-
New South Wales
-
Westmead, New South Wales, Australië, 2145
- Werving
- The Children's Hospital at Westmead /ID# 275672
-
-
Western Australia
-
Perth, Western Australia, Australië, 6009
- Werving
- Perth Children'S Hospital /ID# 275673
-
-
-
-
-
Paris, Frankrijk, 75571
- Werving
- Hopital Armand Trousseau /ID# 276231
-
-
New Aquitaine
-
Bordeaux, New Aquitaine, Frankrijk, 33076
- Werving
- Chu Bordeaux - Hopital Pellegrin /ID# 277645
-
-
-
-
Roma
-
Rome, Roma, Italië, 00165
- Werving
- Ospedale Pediatrico Bambino Gesu /ID# 275692
-
-
-
-
-
Taipei, Taiwan, 100
- Werving
- National Taiwan University Hospital /ID# 276635
-
-
-
-
Cambridgeshire
-
Cambridge, Cambridgeshire, Verenigd Koninkrijk, CB2 0QQ
- Werving
- Cambridge University Hospital /ID# 277041
-
-
-
-
California
-
Palo Alto, California, Verenigde Staten, 94304
- Werving
- Lucile Packard Children's Hospital /ID# 276015
-
-
Georgia
-
Atlanta, Georgia, Verenigde Staten, 30329
- Werving
- Children'S Healthcare Of Atlanta - Arthur M. Blank Hospital /ID# 275740
-
-
New York
-
Valhalla, New York, Verenigde Staten, 10595
- Werving
- New York Medical College /ID# 275597
-
-
Tennessee
-
Nashville, Tennessee, Verenigde Staten, 37203
- Werving
- Tristar Centennial Medical Center /ID# 275831
-
-
Texas
-
Dallas, Texas, Verenigde Staten, 75235
- Werving
- Children's Medical Center Dallas /ID# 275930
-
-
-
-
Seoul Teugbyeolsi
-
Seoul, Seoul Teugbyeolsi, Zuid -Korea, 03080
- Werving
- Seoul National University Hospital /ID# 276978
-
Seoul, Seoul Teugbyeolsi, Zuid -Korea, 06351
- Werving
- Samsung Medical Center /ID# 276979
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
-
Must have histologically confirmed acute myeloid leukemia (AML) meeting one of the following disease criteria:
- Second or greater relapse. OR
- Disease refractory to second or subsequent line of therapy (defined as resistant disease after at least one cycle of each treatment regimen).
-
Must have myeloid leukemic blasts that are CD123-positive by flow cytometry as determined by the treating institution.
-
Has >= 5% myeloid leukemic blasts in bone marrow at time of relapse or refractory disease and prior to Screening for this study.
-
Performance status by Lansky (< 16 years old at evaluation) or Karnofsky (>= 16 years old at evaluation) score >= 50 or ECOG score <= 2.
-
May have status of central nervous system (CNS)1, CNS2, or CNS3 disease without clinical signs or neurologic symptoms suggestive of CNS leukemia, such as facial nerve palsy, brain/eye involvement or hypothalamic syndrome. Participants receiving intrathecal therapy and no additional CNS-directed systemic therapy at study entry are eligible and may continue treatment as clinically indicated in accordance with institutional practice.
-
For those participants who have not reached the age of consent, parent or legal guardian with the willingness and ability to provide informed consent and participant willing and able to give assent, as appropriate for age and country.
Exclusion Criteria:
- Known clinically significant cardiac disease.
- Down syndrome.
- Acute promyelocytic leukemia (APL) or juvenile myelomonocytic leukemia (JMML).
- Symptomatic central nervous system (CNS3) disease
- Prior history of any severity veno-occlusive disease/sinusoidal obstructive syndrome (VOD/SOS) of the liver.
- Prior history of hematopoietic stem cell transplant within 6 months prior to Screening without evidence of active GvHD at the time of screening and the participant is off medications to treat or prevent either post-transplant graft-versus-host disease (GvHD) or post-transplant rejection (except for a stable dose of corticosteroids).
- Have received prior Chimeric Antigen Receptor T-cell (CAR-T) therapy.
- Any other known current malignancy requiring therapy.
- Currently receiving anticancer therapy with antineoplastic intent, including radiotherapy, systemic therapy small molecules, monoclonal antibodies, other investigational agents, or high-dose chemotherapy with the exception of intrathecal therapy.
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: Niet-gerandomiseerd
- Interventioneel model: Parallelle opdracht
- Masker: Geen (open label)
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Experimenteel: Cohort 1: Pivekimab Sunirine Ages 2 to < 6 Years
Participants will receive pivekimab sunirine, as part of the approximately 28 month study duration. If enrolled, subjects aged 6 months to less than 2 years will be included in Cohort 1 |
Intravenous |
|
Experimenteel: Cohort 2: Pivekimab Sunirine Ages 6 to < 12 Years
Participants will receive pivekimab sunirine, as part of the approximately 28 month study duration. |
Intravenous |
|
Experimenteel: Cohort 3: Pivekimab Sunirine Ages 12 to < 17 Years
Participants will receive pivekimab sunirine, as part of the approximately 28 month study duration. |
Intravenous |
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Number of Participants with Treatment-Emergent Adverse Events (TEAEs) Leading to Treatment Discontinuation
Tijdsspanne: Up to Approximately 24 Months
|
Number of participants with protocol specified Treatment-Emergent Adverse Events (TEAEs) during and after treatment with pivekimab sunirine (PVEK). Severity of TEAEs will be graded according to the National Cancer Institute (NCI) Common Toxicity Criteria for Adverse Events (CTCAE) version 5.0. |
Up to Approximately 24 Months
|
|
Maximum Observed Serum/Plasma Concentration (Cmax) of Intact Antibody-Drug Conjugate (ADC)
Tijdsspanne: Up to Approximately 22 Months
|
Maximum observed serum/plasma concentration of intact ADC. |
Up to Approximately 22 Months
|
|
Cmax of FGN849 Payload
Tijdsspanne: Up to Approximately 22 Months
|
Maximum observed serum/plasma concentration of FGN849 payload. |
Up to Approximately 22 Months
|
|
Area Under the Concentration-Time Curve (AUC) of Intact ADC
Tijdsspanne: Up to Approximately 22 Months
|
Area under the concentration-time curve of intact ADC. |
Up to Approximately 22 Months
|
|
AUC of FGN849 payload
Tijdsspanne: Up to Approximately 22 Months
|
Area under the concentration-time curve of FGN849 payload. |
Up to Approximately 22 Months
|
|
Time to Cmax (Tmax) of Intact ADC
Tijdsspanne: Up to Approximately 22 Months
|
Time to Cmax of intact ADC. |
Up to Approximately 22 Months
|
|
Tmax of FGN849 Payload
Tijdsspanne: Up to Approximately 22 Months
|
Time to Cmax of payload. |
Up to Approximately 22 Months
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Percentage of Participants Achieving Complete Remission (CR)
Tijdsspanne: Up to Approximately 28 Months
|
CR is defined as Hematologic recovery: Absolute Neutrophil Count (ANC) > 1.0 × 10^9/L (> 1,000/μL) and platelet count > 100 × 10^9/L (> 100,000/μL); < 5% bone marrow blasts; absence of circulating blasts; no evidence of extramedullary disease; no transfusions or support by exogenous growth factors (GCSF) within 7 days prior to response evaluation. |
Up to Approximately 28 Months
|
|
Percentage of Participants Achieving Composite Complete Remission (CR + complete remission with incomplete recovery [CRi])
Tijdsspanne: Up to Approximately 28 Months
|
Percentage of participants achieving CR + CRi. |
Up to Approximately 28 Months
|
|
Percentage of Participants Achieving Composite Complete Remission (CR + complete remission with partial hematological [CRh])
Tijdsspanne: Up to Approximately 28 Months
|
Percentage of participants achieving CR + CRh. |
Up to Approximately 28 Months
|
|
Duration of Complete Remission (DOCR)
Tijdsspanne: Up to Approximately 28 Months
|
DOCR is defined as the first response of CR to the time of relapse or death from any cause, whichever comes first; for participants who did not relapse or die, the duration will be censored at the time of the last response assessment. |
Up to Approximately 28 Months
|
|
Duration of Composite Complete Remission (CR + CRi)
Tijdsspanne: Up to Approximately 28 Months
|
Duration of composite complete remission (CR + CRi). |
Up to Approximately 28 Months
|
|
Duration of Composite Complete Remission (CR + CRh)
Tijdsspanne: Up to Approximately 28 Months
|
Duration of composite complete remission (CR + CRh). |
Up to Approximately 28 Months
|
Medewerkers en onderzoekers
Sponsor
Onderzoekers
- Studie directeur: ABBVIE INC., AbbVie
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Geschat)
Studie voltooiing (Geschat)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
- M25-692
- 2024-520125-36 (Andere identificatie: EU CT)
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
product vervaardigd in en geëxporteerd uit de V.S.
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .